News

Shire attacks treatment monopoly of Sanofi
Enlarge image

BusinessFranceIrelandUK

Shire attacks treatment monopoly of Sanofi

29.06.2012 - For over a decade, Sanofi’s Cerezyme has dominated the market of therapies for Gaucher disease. Now, Shire challenges the drug with new results.

Dublin/Paris/ Carmiel/ Cambridge – Results from a head-to-head Phase III clinical study with Sanofi’s Gaucher disease therapy imiglucerase (Cerezyme) suggest that Shire’s enzyme replacement therapy velaglucerase alfa (VPRIV) offers a unique benefit to patients. According to the Irish drugmaker, only patients treated with VPRIV experienced statistically significant improvement in lumbar spine bone mineral density after nine months of treatment. This, together with a 15% lower price than Aventis‘ expensive type 1 Gaucher treatment could give the Irish an advantage in the market for the rare disease, that is narrow but lucrative.

Until VPRIV was approved in 40 countries, Aventis subsidiary Genzyme was able to charge $200,000 per year per patient for its treatment that dates back to 1997, but other players are now trying to get a piece of the cake. Pfizer and its development partner Protalix currently got US market authorisation for its plant-cell based enzyme expression therapy Elelyso (taliglucerase alfa) but it was rebuffed at the end of June by the EMA. VPRIV is made in a human cell line using Shire’s gene activation technology.

Type 1 Gaucher disease is caused by a lack of the enzyme β-glucocerebrosidase, which normally breaks down a fatty waste product called glucosylceramide. Without the enzyme, glucosylceramide builds up in the body, typically in the liver, spleen and bone marrow, which produces the symptoms of the disease: anaemia (low red blood cell counts), tiredness, easy bruising and a tendency to bleed, an enlarged spleen and liver, and bone pain and breaks. The latter symptoms are now addressed by Shires enzyme replacement therapy, according to surrogate marker data presented at the European Working Group on Gaucher Disease (EWGGD) meeting in Paris.

BusinessSwitzerlandUK

23.04.2014 In an effort to focus on key businesses, pharma giant Novartis is joining forces with long-time rival GlaxoSmithKline in a multi-billion Euro asset exchange and an OTC joint venture.

FinanceSwedenFrance

18.04.2014 Oxthera AB, a Swedish biopharma company with a focus on rare diseases, has gained a SEK70m cash injection to continue its clinical programme for primary hyperoxaluria.

FundingEU

17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.

BusinessGermanyFrance

15.04.2014 German flavour and scent specialist Symrise has announced its plans to acquire French pet-food ingredients maker Diana Group for €1.3bn.

BioeconomySpain

14.04.2014 Spanish Neol Biosolutions and the Center for Second Generation Biofuels are starting a partnership to scale-up Neol's waste-to-oil technology.

EvidenceUKSwitzerland

11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.

BusinessSwitzerlandSpain

09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.

Status ReportSwitzerland

08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.

NanobiotechnologyItaly

07.04.2014 Scientists from the University of Udine have designed, produced and tested a prototype for a "DNA origami" nanorobot that can potentially deliver biological activators in-vivo.

EpidemicEUFranceGermanyItaly

02.04.2014 As the Ebola epidemic in Guinea worsens, Europe is deploying the specialists of EMLab to provide diagnostics at the focus of the outbreak.

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)344.00 GBP12.6%
  • THERAMETRICS (CH)0.11 CHF10.0%
  • ACTIVE BIOTECH (S)35.60 SEK9.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • GENFIT (F)22.42 EUR-8.1%
  • BAVARIAN NORDIC (D)13.63 EUR-6.4%

TOP

  • BIOTECH PHARMACON (N)19.00 NOK73.5%
  • WILEX (D)0.81 EUR42.1%
  • E-THERAPEUTICS (UK)28.00 GBP40.0%

FLOP

  • CYTOS (CH)0.16 CHF-94.1%
  • BIONOR PHARMA (N)2.17 NOK-45.7%
  • IMMUNICUM AB (S)16.40 SEK-36.9%

TOP

  • SILENCE THERAPEUTICS (UK)257.25 GBP6174.4%
  • IXICO (UK)66.50 GBP737.5%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.16 CHF-96.1%
  • EVOCUTIS (UK)0.22 GBP-91.8%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 23.04.2014